Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Moodys
Dow
AstraZeneca
Johnson and Johnson

Last Updated: June 26, 2022

CLINICAL TRIALS PROFILE FOR ISTODAX


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Istodax

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00053963 ↗ FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Completed National Cancer Institute (NCI) Phase 1 2002-09-01 This phase I trial is studying the side effects and best dose of FR901228 in treating children with refractory or recurrent solid tumors or leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die
NCT00062075 ↗ Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed National Cancer Institute (NCI) Phase 2 2003-05-01 This phase II trial is studying how well romidepsin works in treating patients with relapsed or refractory acute myeloid leukemia. Drugs used in chemotherapy, such as romidepsin, work in different ways to stop tumor cells from dividing so they stop growing or die.
NCT00079443 ↗ FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma Terminated National Cancer Institute (NCI) Phase 2 2004-01-01 This phase I/II trial is studying the best dose of FR901228 when given together with rituximab and fludarabine and to see how well FR901228 works alone in treating patients with relapsed or refractory low-grade B-cell non-Hodgkin's lymphoma. Drugs used in chemotherapy, such as FR901228 and fludarabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Rituximab may increase the effectiveness of chemotherapy drugs by making cancer cells more sensitive to the drugs.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Istodax

Condition Name

Condition Name for Istodax
Intervention Trials
Lymphoma 5
Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma 5
Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Istodax
Intervention Trials
Lymphoma 27
Lymphoma, T-Cell 21
Lymphoma, T-Cell, Peripheral 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Istodax

Trials by Country

Trials by Country for Istodax
Location Trials
United States 105
United Kingdom 4
France 3
Germany 2
Denmark 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Istodax
Location Trials
New York 11
California 10
Texas 8
Ohio 8
Illinois 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Istodax

Clinical Trial Phase

Clinical Trial Phase for Istodax
Clinical Trial Phase Trials
Phase 3 2
Phase 2 16
Phase 1/Phase 2 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Istodax
Clinical Trial Phase Trials
Completed 18
Terminated 11
Recruiting 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Istodax

Sponsor Name

Sponsor Name for Istodax
Sponsor Trials
National Cancer Institute (NCI) 22
Celgene Corporation 10
Celgene 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Istodax
Sponsor Trials
Other 50
Industry 26
NIH 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Harvard Business School
Colorcon
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.